论文部分内容阅读
将202例行冠状动脉支架置入术的冠心病患者随机分为观察组99例及对照组103例,围术期分别予血脂康胶囊及阿托伐他汀口服。观察两组疗效、支架再狭窄发生率、主要不良心脏事件(MACE)发生率等。结果随访6~9个月,两组MACE发生率及支架内再狭窄发生率比较P均>0.05。认为血脂康预防冠心病支架置入术后再狭窄效果与阿托伐他汀相似,且价格低廉。
A total of 202 coronary artery disease patients undergoing coronary stenting were randomly divided into observation group (n = 99) and control group (n = 103). Perioperative period, Xuezhikang capsules and atorvastatin were given orally. The curative effect, the incidence of stent restenosis and the incidence of major adverse cardiac events (MACE) were observed. Results The follow-up ranged from 6 to 9 months. The incidence of MACE and the incidence of in-stent restenosis in both groups were all significantly higher than 0.05. That Xuezhikang prevent coronary stent restenosis after coronary stenting and atorvastatin similar, and the price is low.